玻璃体腔注射雷珠单抗、阿柏西普和贝伐珠单抗对眼压的12个月和24个月影响:一项网状Meta分析
该网状Meta分析纳入26项随机对照试验共12522只眼,比较抗血管内皮生长因子(VEGF)药物与对照对眼压的影响。结果显示抗VEGF药物与对照在12和24个月时眼压升高方面无明确差异,但证据确定性受不精确性限制。
要点
- 在84项抗VEGF药物间比较的网状估计中,83项显示眼压结局无统计学显著差异。
- 雷珠单抗0.5 mg在12个月时眼压≥30 mmHg的发生率高于贝伐珠单抗(低确定性证据)。
- 抗VEGF药物与对照的56项网状估计中,53项显示无统计学显著差异,但不精确性不能排除重要临床效应。
核心结论
- 该网状Meta分析未显示抗VEGF药物与对照在治疗开始后12和24个月眼压升高方面存在明确差异。
- 证据的不精确性妨碍了确定性结论。
研究设计与样本
- 研究纳入比较抗VEGF药物之间或与对照的随机对照试验,适应症为新生血管性年龄相关性黄斑变性、视网膜静脉阻塞或糖尿病性黄斑水肿。
- 共纳入26项随机对照试验,12522只眼,分析药物包括阿柏西普、贝伐珠单抗、雷珠单抗0.3 mg和0.5 mg以及非注射对照。
- 采用配对Meta分析和贝叶斯网状Meta分析,并使用推荐分级的评估、制定与评价(GRADE)方法评估证据确定性。
主要发现
- 在抗VEGF药物间比较的84项网状估计中,83项显示无统计学显著差异(低至中等确定性证据)。
- 雷珠单抗0.5 mg在12个月时眼压≥30 mmHg的发生率高于贝伐珠单抗(低确定性证据)。
- 在抗VEGF药物与对照比较的56项网状估计中,53项显示无统计学显著差异(低至中等确定性证据)。
- 雷珠单抗0.5 mg在24个月时连续访视眼压较基线升高≥5 mmHg的发生率更高(低确定性证据),在12和24个月时按临床医生判断的眼压升高发生率更高(确定性分别为低和极低)。
- 无统计学显著效应的比较中,95%可信区间未排除重要临床效应。
关键数值与推荐
- 眼压结局包括:连续访视较基线升高≥5 mmHg、任一次访视较基线升高≥10 mmHg、连续访视≥21 mmHg、任一次访视≥25 mmHg、任一次访视≥30 mmHg、启动降眼压药物、按临床医生判断的眼压升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无统计学显著效应的比较中,95%可信区间未排除重要临床效应。
- 这些比较的证据确定性受不精确性限制。
- 证据的不精确性妨碍了确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: To investigate the effect of anti-vascular endothelial growth factor (VEGF) therapy on intraocular pressure (IOP) 12 and 24 months after initiation. CLINICAL RELEVANCE: It is unclear whether serial anti-VEGF injections result in sustained IOP increases. METHODS: Randomized controlled trials (RCTs) comparing anti-VEGF agents with each other or with controls for the treatment of neovascular age-related macular degeneration, retinal vein occlusions, or diabetic macular edema were included. Pairwise meta-analysis and Bayesian network meta-analysis examined the proportion of patients whose IOP (1) increased 5 mmHg or more from baseline on consecutive visits, (2) increased 10 mmHg or more from baseline at any visit, (3) was 21 mmHg or more on consecutive visits, (4) was 25 mmHg or more at any visit, (5) was 30 mmHg or more at any visit, (6) prompted initiation of IOP-lowering medications, or (7) increased as per the clinicians' discretion. Grading of Recommendations Assessments, Development, and Evaluations methodology informed the certainty of evidence. RESULTS: Twenty-six RCTs of 12 522 eyes were included. Aflibercept, bevacizumab, ranibizumab (0.3 mg and 0.5 mg), and noninjection controls were analyzed. Eighty-three of 84 network estimates for comparisons between anti-VEGF agents demonstrated no statistically significant difference (low to moderate certainty of evidence). Ranibizumab 0.5 mg showed higher rates than bevacizumab of IOP measurements of 30 mmHg or more at 12 months (low certainty of evidence). Fifty-three of 56 network estimates for comparisons between anti-VEGF agents and controls demonstrated no statistically significant difference (low to moderate certainty of evidence). Ranibizumab 0.5 mg showed higher rates of consecutive IOP increases of 5 mmHg or more at 24 months (low certainty of evidence) and higher rates of IOP increases as per the clinicians' discretion at 12 and 24 months (low and very low certainty of evidence, respectively). The 95% credible intervals in comparisons without statistically significant effects did not rule out important clinical effects. The certainty of evidence in these comparisons is limited by imprecision. CONCLUSION: This network meta-analysis does not show any clear difference in IOP increases 12 and 24 months after treatment initiation between anti-VEGF agents and controls. Imprecision precludes definitive conclusions.
引用
- Nanji K, Sarohia GS, Kennedy K, et al. The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure: A Network Meta-Analysis. Ophthalmology. 2021. PMID: 34871637. doi:10.1016/j.ophtha.2021.11.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。